Our priority projects include trials of drugs that are closest to reaching the clinic, as well as the projects that need funding most urgently. This includes pre-clinical and clinical trials.

Exenatide

In 2017 results of a large phase ll trial showed that exenatide, a drug used to treat diabetes, may slow the progression of Parkinson’s. Cure Parkinson’s has been at the forefront of the exenatide journey in Parkinson’s since the start. We funded the first ever clinical study of exenatide in people with Parkinson’s; we are now supporting two sub-studies in the upcoming phase lll clinical trial.

Exenatide and Parkinson’s
Ambroxol

Based on evidence that this simple cough medicine offers potential as a treatment for Parkinson’s, our International Linked Clinical Trials committee prioritised ambroxol for clinical evaluation in Parkinson’s. A UK-based clinical trial, co-funded by Cure Parkinson’s – together with international efforts – now suggests ambroxol as a promising avenue in our search for treatments to halt the progression of Parkinson’s.

Ambroxol and Parkinson’s
UDCA
UDCA

UDCA is used to treat liver disease. This trial will establish if UDCA is safe and tolerable at the dose needed to reach the brain. It will also see if it can preserve or improve the chemistry in the brain, and whether this translates into improvements in patients’ movement and mobility.

UDCA and Parkinson’s
Nortriptyline
Nortriptyline

A number of small studies have suggested that a class of antidepressants called ‘tricyclics’ may be more effective than others at treating depression in people with Parkinson’s. Evidence is mounting that they could also protect dopamine neurons in the brain; the crucial cells that are damaged and lost in Parkinson’s. Now Cure Parkinson’s is funding a sub-study of the main phase ll trial, to investigate the critical question of whether nortriptyline can alter the course of the disease.

Nortriptyline and Parkinson’s
Iron Removing Medications (Iron Chelation)

Removing excess iron from the body has powerful antioxidant effects known to dramatically increase cell survival. It is hoped that decreasing the levels of iron in the brain will improve symptoms and decrease the rate of progression of Parkinson’s.

Iron Chelation and Parkinson’s
Brain Growth Factors

Nerve growth or neurotrophic factors are small proteins that support neurons and encourage their growth and survival during development. Cure Parkinson’s is supporting a pre-clinical study focused on a brain growth factor called cerebral dopamine neurotrophic factor or CDNF.

Neurotrophic Factors for Parkinson’s

Our International Linked Clinical Trials Programme (iLCT)

Our iLCT programme screens multiple prospective new treatments for Parkinson’s.

Find Out More

The Australian Parkinson’s Mission (APM)

In January 2019, the Australian Parkinson’s Mission – an international collaboration between the Garvan Institute of Medical Research, Shake It Up Australia Foundation, Parkinson’s Australia, Cure Parkinson’s and the Michael J. Fox Foundation for Parkinson’s – was awarded a A$30 million government grant to identify and fast-track better treatments for Parkinson’s. This innovative Australian-led programme of research expands the global International Linked Clinical Trials programme spearheaded by Cure Parkinson’s and establishes a first step towards personalised medicine providing an opportunity to deliver multiple clinical trials that incorporate advanced genetic and biomarker studies in a way that has not been done before.

Associate Professor Anthony Cooper, Garvan Institute of Medical Research

Take Part in Research

Find out more about research studies and clinical trials recruiting and the different ways you can get involved in Parkinson’s research.

Take Part in Research